Article Figures & Data
Figures
- Fig 1.
Overlap of tumor lesions. Overlap of all 182 patients with low-grade gliomas included in our study (A), overlap of a subgroup of 116 patients with mutant p53 gliomas (B), and overlap of a subgroup of 66 patients with wild-type p53 gliomas (C). The color range indicates the proportion of overlap of different cohorts, from violet (1 case) to red (>25% of cases overlap). Brain sections are displayed from z-coordinates −32 to +58 in the MNI space.
- Fig 2.
Power map for voxel-based lesion-symptom mapping analysis. The color map on the MNI space shows the distribution of power, ranging from 0 (violet) to 1 (red), with α set to P < .05. Only voxels with high-power values (>0.8) were included in the VLSM analysis.
- Fig 3.
Voxel-based lesion-symptom mapping–defined p53 high-mutant regions. VLSM analysis shows regions associated with high expression of mutant p53 in low-grade gliomas. The left-medial temporal lobe and right-anterior temporal lobes are significantly correlated to high mutant p53 expression. The color range indicates the level of t values from red to yellow (least to most significant). Only significant voxels are rendered on the basis of a critical threshold determined by permutation testing (n = 500, P < .05).
- Fig 4.
Kaplan-Meier curves showing the PFS for patients with low-grade gliomas. A, No significant difference was observed between patients with wild-type p53 tumors and those with mutant p53 tumors (log-rank, P = .2994). B, A statistically significant difference in PFS was observed between patients with tumors in VLSM-identified regions and patients with tumors located outside VLSM-identified regions (log-rank, P = .0269). C, Among patients with tumors located in VLSM-identified regions, a trend toward a difference in PFS was observed between patients with wild-type p53 tumors and those with mutant p53 tumors (log-rank, P = .1032). D, Among patients with mutant p53 tumors, a significantly worse PFS was observed in patients with tumors located in VLSM-identified regions compared with patients with tumors outside these regions (log-rank, P = .0088).
Tables
Clinical characteristics of patients
Characteristics Status of p53 P Value Mutated (%) (n = 116) Wild-Type (%) (n = 66) Age 40 yr and older 41 (55) 33 (45) .028 Younger than 40 yr 75 (69) 33 (31) Sex Male 70 (65) 37 (35) .469 Female 46 (61) 29 (39) History of seizures Yes 70 (62) 42 (38) .378 No 46 (66) 24 (34) Preoperative KPS ≥80 109 (65) 58 (35) .499 <80 7 (47) 8 (53) Pathology Oligodendroglioma 10 (36) 18 (64) .003 Astrocytoma 48 (76) 15 (24) Oligoastrocytoma 58 (64) 33 (36) Note:—KPS indicates Karnofsky Performance Status Scale.
Jump to section
Related Articles
Cited By...
- No citing articles found.